Erratum: A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma (Journal of the American Academy of Dermatology (2015) 73 (99-105))

H. Sofen; K. G. Gross; L. H. Goldberg

doi:10.1016/j.jaad.2015.10.001

Erratum: A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma (Journal of the American Academy of Dermatology (2015) 73 (99-105))

H. Sofen, K. G. Gross, L. H. Goldberg

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	780
Number of pages	1
Journal	Journal of the American Academy of Dermatology
Volume	74
Issue number	4
DOIs	https://doi.org/10.1016/j.jaad.2015.10.001
State	Published - Apr 1 2016

ASJC Scopus subject areas

Dermatology

Access to Document

10.1016/j.jaad.2015.10.001

Cite this

Erratum: A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma (Journal of the American Academy of Dermatology (2015) 73 (99-105)). / Sofen, H.; Gross, K. G.; Goldberg, L. H.
In: Journal of the American Academy of Dermatology, Vol. 74, No. 4, 01.04.2016, p. 780.

Research output: Contribution to journal › Comment/debate › peer-review

Sofen, H, Gross, KG & Goldberg, LH 2016, 'Erratum: A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma (Journal of the American Academy of Dermatology (2015) 73 (99-105))', Journal of the American Academy of Dermatology, vol. 74, no. 4, pp. 780. https://doi.org/10.1016/j.jaad.2015.10.001

@article{4af774bba76c4c5eb2cab10450a2bfad,

title = "Erratum: A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma (Journal of the American Academy of Dermatology (2015) 73 (99-105))",

author = "H. Sofen and Gross, {K. G.} and Goldberg, {L. H.}",

year = "2016",

month = apr,

day = "1",

doi = "10.1016/j.jaad.2015.10.001",

language = "English (US)",

volume = "74",

pages = "780",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Erratum

T2 - A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma (Journal of the American Academy of Dermatology (2015) 73 (99-105))

AU - Sofen, H.

AU - Gross, K. G.

AU - Goldberg, L. H.

PY - 2016/4/1

Y1 - 2016/4/1

UR - http://www.scopus.com/inward/record.url?scp=84960392929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960392929&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2015.10.001

DO - 10.1016/j.jaad.2015.10.001

M3 - Comment/debate

AN - SCOPUS:84960392929

SN - 0190-9622

VL - 74

SP - 780

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 4

ER -

Erratum: A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma (Journal of the American Academy of Dermatology (2015) 73 (99-105))

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this